BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16228637)

  • 1. Pain recurrence on the third day after application of a transdermal fentanyl patch.
    Konishi H; Ishihara C; Chiba M; Endo Y; Yamaji A
    Pharm World Sci; 2005 Aug; 27(4):353. PubMed ID: 16228637
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor pain. Fentanyl TTS: a transdermal system for tumor pain therapy].
    Dtsch Med Wochenschr; 1995 Oct; 120(41 Suppl):1-4. PubMed ID: 9022357
    [No Abstract]   [Full Text] [Related]  

  • 3. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
    Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
    Payne R
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Opioid intoxication. Inappropriate administration of transdermal fentanyl].
    Klockgether-Radke A; Hildebrandt J
    Anaesthesist; 1997 May; 46(5):428-9. PubMed ID: 9245212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
    Hata A; Katakami N; Masuda Y; Nanjo S; Otsuka K; Kaji R; Fujita S; Iwamori S; Mifune Y; Orita H; Fukae M; Yamatani T
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):415-8. PubMed ID: 21403444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal fentanyl for severe cancer-related pain.
    Yeo W; Lam KK; Chan AT; Leung TW; Nip SY; Johnson PJ
    Palliat Med; 1997 May; 11(3):233-9. PubMed ID: 9205657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis.
    Berliner MN; Giesecke T; Bornhövd KD
    Clin J Pain; 2007; 23(6):530-4. PubMed ID: 17575494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
    Koike K; Terui T; Nagasako T; Horiuchi I; Machino T; Kusakabe T; Hirayama Y; Mihara H; Yamakage M; Kato J; Nishisato T; Ishitani K
    Support Care Cancer; 2016 Mar; 24(3):1053-9. PubMed ID: 26248654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].
    Huang HQ; Cai QQ; Lin XB; Wang BF; Bu Q; Gao Y; Peng YL
    Ai Zheng; 2007 Apr; 26(4):390-3. PubMed ID: 17430658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose fentanyl patch for cancer pain.
    Menahem S; Shvartzman P
    J Am Board Fam Pract; 2004; 17(5):388-90. PubMed ID: 15355954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
    Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
    Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
    Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
    J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cancer-related pain with transdermal fentanyl.
    Leelanuntakit S
    J Med Assoc Thai; 1996 Jun; 79(6):341-6. PubMed ID: 8855606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain.
    Zeppetella G
    Palliat Med; 2000 Jan; 14(1):57-8. PubMed ID: 10717724
    [No Abstract]   [Full Text] [Related]  

  • 18. Fentanyl nasal spray (Lazanda) for pain.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of cancer pain with transdermal fentanyl.
    Donner B; Zenz M; Strumpf M; Raber M
    J Pain Symptom Manage; 1998 Mar; 15(3):168-75. PubMed ID: 9564118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.
    Radbruch L; Sabatowski R; Petzke F; Brunsch-Radbruch A; Grond S; Lehmann KA
    Palliat Med; 2001 Jul; 15(4):309-21. PubMed ID: 12054148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.